Related references
Note: Only part of the references are listed.Cost-effectiveness and budget impact analysis of siponimod in the treatment of secondary progressive multiple sclerosis in Italy
Paolo Angelo Cortesi et al.
PLOS ONE (2022)
Intranasal anti-caspase-1 therapy preserves myelin and glucose metabolism in a model of progressive multiple sclerosis
Leina B. Saito et al.
GLIA (2021)
Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO
Ekaterina Gibiansky et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Intranasal administration of small extracellular vesicles derived from mesenchymal stem cells ameliorated the experimental autoimmune encephalomyelitis
Anwar Fathollahi et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2021)
Intranasal delivery of interferon-β-loaded nanoparticles induces control of neuroinflammation in a preclinical model of multiple sclerosis: A promising simple, effective, non-invasive, and low-cost therapy
Luis F. Gonzalez et al.
JOURNAL OF CONTROLLED RELEASE (2021)
An Exposure-Response Analysis of the Clinical Efficacy of Ponesimod in a Randomized Phase II Study in Patients with Multiple Sclerosis
Per Olsson Gisleskog et al.
CLINICAL PHARMACOKINETICS (2021)
Ponesimod: First Approval
Anthony Markham
DRUGS (2021)
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study A Randomized Clinical Trial
Ludwig Kappos et al.
JAMA NEUROLOGY (2021)
Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis
Izanne Roos et al.
NEUROLOGY (2021)
Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study
Thais G. Moreira et al.
FRONTIERS IN IMMUNOLOGY (2021)
Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis
Izanne Roos et al.
NEUROLOGY (2021)
Safety Assessment of AAV2-hGDNF Administered Via Intracerebral Injection in Rats for Treatment of Parkinson's Disease
Pramod S. Terse et al.
INTERNATIONAL JOURNAL OF TOXICOLOGY (2021)
Intranasal delivery of SDF-1α-preconditioned bone marrow mesenchymal cells improves remyelination in the cuprizone-induced mouse model of multiple sclerosis
Fatemeh Beigi Boroujeni et al.
CELL BIOLOGY INTERNATIONAL (2020)
Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study
Robert T. Naismith et al.
CNS DRUGS (2020)
Intracerebral implantation of human neural stem cells and motor recovery after stroke: multicentre prospective single-arm study (PISCES-2)
Keith W. Muir et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2020)
Treatment effects of fingolimod in multiple sclerosis: Selective changes in peripheral blood lymphocyte subsets
Maria Hjorth et al.
PLOS ONE (2020)
The 2013 clinical course descriptors for multiple sclerosis A clarification
Fred D. Lublin et al.
NEUROLOGY (2020)
Glatiramer acetate immune modulates B-cell antigen presentation in treatment of MS
Darius Haeusler et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)
Revisiting the blood-brain barrier: A hard nut to crack in the transportation of drug molecules
Seetha Harilal et al.
BRAIN RESEARCH BULLETIN (2020)
Intranasal administration of conditioned medium derived from mesenchymal stem cells-differentiated oligodendrocytes ameliorates experimental autoimmune encephalomyelitis
Maryam Borhani-Haghighi et al.
JOURNAL OF CHEMICAL NEUROANATOMY (2020)
Ofatumumab versus Teriflunomide in Multiple Sclerosis
Stephen L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Endovascular model of ischemic stroke in swine guided by real-time MRI
D. Golubczyk et al.
SCIENTIFIC REPORTS (2020)
The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis
Robert Hermann et al.
CLINICAL PHARMACOKINETICS (2019)
Nasal delivery of Fasudil-modified immune cells exhibits therapeutic potential in experimental autoimmune encephalomyelitis
Shang-De Guo et al.
CNS NEUROSCIENCE & THERAPEUTICS (2019)
Nanostructured lipid carriers engineered for intranasal delivery of teriflunomide in multiple sclerosis: optimization and in vivo studies
Dnyandev G. Gadhave et al.
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY (2019)
Modulating acute neuroinflammation in intracerebral hemorrhage: the potential promise of currently approved medications for multiple sclerosis
Jarred Napier et al.
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY (2019)
LINGO-1 siRNA nanoparticles promote central remyelination in ethidium bromide-induced demyelination in rats
Alaa Eldin H. Youssef et al.
JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY (2019)
Siponimod (BAF312) Treatment Reduces Brain Infiltration but Not Lesion Volume in Middle-Aged Mice in Experimental Stroke
Antje Vogelgesang et al.
STROKE (2019)
Results from Phase I Clinical Trial with Intraspinal Injection of Neural Stem Cells in Amyotrophic Lateral Sclerosis: A Long-Term Outcome
Letizia Mazzini et al.
STEM CELLS TRANSLATIONAL MEDICINE (2019)
PET imaging of distinct brain uptake of a nanobody and similarly-sized PAMAM dendrimers after intra-arterial administration
Wojciech G. Lesniak et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Intranasal Delivery of Mesenchymal Stem Cell Derived Exosomes Loaded with Phosphatase and Tensin Homolog siRNA Repairs Complete Spinal Cord Injury
Shaowei Guo et al.
ACS NANO (2019)
Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes
Anne Gardin et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2019)
The therapeutic effect of platelet-rich plasma on the experimental autoimmune encephalomyelitis mice
Maryam Borhani-Haghighi et al.
JOURNAL OF NEUROIMMUNOLOGY (2019)
Adeno-associated viral vector serotype 9-based gene therapy for Niemann-Pick disease type A
Lluis Samaranch et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Mucosal Administration of E-selectin Limits Disability in Models of Multiple Sclerosis
Jacqueline A. Quandt et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2019)
Intra-arterial Administration of Human Umbilical Cord Blood Derived Cells Inversed Learning Asymmetry Resulting From Focal Brain Injury in Rat
Elzbieta Gomicka-Pawlak et al.
FRONTIERS IN NEUROLOGY (2019)
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial
Giancarlo Comi et al.
LANCET NEUROLOGY (2019)
Treatment of the bone marrow stromal stem cell supernatant by nasal administration-a new approach to EAE therapy
Xi Wang et al.
STEM CELL RESEARCH & THERAPY (2019)
A Distinct Advantage to Intraarterial Delivery of 89Zr-Bevacizumab in PET Imaging of Mice With and Without Osmotic Opening of the Blood-Brain Barrier
Wojciech G. Lesniak et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
Mitchell T. Wallin et al.
LANCET NEUROLOGY (2019)
Mechanism of Siponimod: Anti-Inflammatory and Neuroprotective Mode of Action
Newshan Behrangi et al.
CELLS (2019)
Real-Time, in Vivo Correlation of Molecular Structure with Drug Distribution in the Brain Striatum Following Convection Enhanced Delivery
Umberto Tosi et al.
ACS CHEMICAL NEUROSCIENCE (2019)
Overexpression of VLA-4 in glial-restricted precursors enhances their endothelial docking and induces diapedesis in a mouse stroke model
Anna Jablonska et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2018)
The Xenopus tadpole: An in vivo model to screen drugs favoring remyelination
Abdelkrim Mannioui et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
The Xenopus tadpole: An in vivo model to screen drugs favoring remyelination
Abdelkrim Mannioui et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Intermittent convection-enhanced delivery of GDNF into rhesus monkey putamen: absence of local or cerebellar toxicity
Matthias Luz et al.
ARCHIVES OF TOXICOLOGY (2018)
Teriflunomide promotes oligodendroglial differentiation and myelination
Peter Goettle et al.
JOURNAL OF NEUROINFLAMMATION (2018)
Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis
Neil H. Riordan et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
Ludwig Kappos et al.
LANCET (2018)
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
Raja Kapoor et al.
LANCET NEUROLOGY (2018)
Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis The MIRROR study
Amit Bar-Or et al.
NEUROLOGY (2018)
Interferon β for Multiple Sclerosis
Dejan Jakimovski et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)
Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis
Elizabeth A. Mills et al.
FRONTIERS IN NEUROLOGY (2018)
Phase I Trial of Intrathecal Mesenchymal Stem Cell-derived Neural Progenitors in Progressive Multiple Sclerosis
Violaine K. Harris et al.
EBIOMEDICINE (2018)
MRI-guided intracerebral convection-enhanced injection of gliotoxins to induce focal demyelination in swine
Lukasz Kalkowski et al.
PLOS ONE (2018)
Fingolimod reduces circulating tight-junction protein levels and in vitro peripheral blood mononuclear cells migration in multiple sclerosis patients
Pasquale Annunziata et al.
SCIENTIFIC REPORTS (2018)
Immunophenotype and Transcriptome Profile of Patients With Multiple Sclerosis Treated With Fingolimod: Setting Up a Model for Prediction of Response in a 2-Year Translational Study
Irene Moreno-Torres et al.
FRONTIERS IN IMMUNOLOGY (2018)
MRI-guided intrathecal transplantation of hydrogel-embedded glial progenitors in large animals
Izabela Malysz-Cymborska et al.
SCIENTIFIC REPORTS (2018)
Transplanted human glial-restricted progenitors can rescue the survival of dysmyelinated mice independent of the production of mature, compact myelin
Agatha Lyczek et al.
EXPERIMENTAL NEUROLOGY (2017)
Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator
Jonathan Q. Tran et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
S. L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
X. Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Oral teriflunomide in the treatment of relapsing forms of multiple sclerosis: clinical evidence and long-term experience
Aaron E. Miller
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2017)
Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis
Radojka M. Savic et al.
CLINICAL PHARMACOKINETICS (2017)
The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis
Samuel F. Hunter et al.
CNS DRUGS (2016)
Long-Term Effects of Repeated Cycles of Intrathecal Triamcinolone Acetonide on Spasticity in MS Patients
Paulus Stefan Rommer et al.
CNS NEUROSCIENCE & THERAPEUTICS (2016)
Predicting and optimizing the territory of blood-brain barrier opening by superselective intra-arterial cerebral infusion under dynamic susceptibility contrast MRI guidance
Miroslaw Janowski et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2016)
Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity
F. L. Scott et al.
BRITISH JOURNAL OF PHARMACOLOGY (2016)
Clinical pharmacology, efficacy, and safety aspects of sphingosine-1-phosphate receptor modulators
Pierre-Eric Juif et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)
Interferon-β therapy specifically reduces pathogenic memory B cells in multiple sclerosis patients by inducing a FAS-mediated apoptosis
Fabiana Rizzo et al.
IMMUNOLOGY AND CELL BIOLOGY (2016)
In vivo and invitro effects of multiple sclerosis immunomodulatory therapeutics on glutamatergic excitotoxicity
Dirk Luchtman et al.
JOURNAL OF NEUROCHEMISTRY (2016)
Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis
Antonietta Gentile et al.
JOURNAL OF NEUROINFLAMMATION (2016)
In vitro evaluation of physiologically relevant concentrations of teriflunomide on activation and proliferation of primary rodent microglia
Tanja Wostradowski et al.
JOURNAL OF NEUROINFLAMMATION (2016)
Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial
Jeffrey A. Cohen et al.
LANCET NEUROLOGY (2016)
The effects of intrathecal rituximab on biomarkers in multiple sclerosis
Joanne Topping et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2016)
Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases
Daniele D'Ambrosio et al.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2016)
A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity
Federica Esposito et al.
ANNALS OF NEUROLOGY (2015)
High interindividual variability in the CD4/CD8 T cell ratio and natalizumab concentration levels in the cerebrospinal fluid of patients with multiple sclerosis
A. Harrer et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2015)
Dimethyl Fumarate Protects Neural Stem/Progenitor Cells and Neurons from Oxidative Damage through Nrf2-ERK1/2 MAPK Pathway
Qin Wang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
Safety and efficacy of reduced fingolimod dosage treatment
Bassem I. Yamout et al.
JOURNAL OF NEUROIMMUNOLOGY (2015)
Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use
Eva Havrdova et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2015)
Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?
Alberto Gajofatto et al.
WORLD JOURNAL OF CLINICAL CASES (2015)
Reassessing the Role of Intra-Arterial Drug Delivery for Glioblastoma Multiforme Treatment
Jason A. Ellis et al.
JOURNAL OF DRUG DELIVERY (2015)
Intranasal delivery of central nervous system-retargeted human mesenchymal stromal cells prolongs treatment efficacy of experimental autoimmune encephalomyelitis
Moa Fransson et al.
IMMUNOLOGY (2014)
Defining the clinical course of multiple sclerosis The 2013 revisions
Fred D. Lublin et al.
NEUROLOGY (2014)
Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing-remitting multiple sclerosis
Serena Ruggieri et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2014)
Anti-CD20 monoclonal antibodies: Beyond B-cells
Irit Avivi et al.
BLOOD REVIEWS (2013)
Interferon beta induces clearance of mutant ataxin 7 and improves locomotion in SCA7 knock-in mice
Alice Chort et al.
BRAIN (2013)
Brain bioavailability of human intravenous immunoglobulin and its transport through the murine blood-brain barrier
Isabelle St-Amour et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2013)
Nasal administration of drugs as a new non-invasive strategy for efficient treatment of multiple sclerosis
Shaher Duchi et al.
JOURNAL OF NEUROIMMUNOLOGY (2013)
Clinical experience with stem cells and other cell therapies in neurological diseases
Dimitrios Karussis et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2013)
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study
Krzysztof Selmaj et al.
LANCET NEUROLOGY (2013)
Investigation of Sequential Growth Factor Delivery during Cuprizone Challenge in Mice Aimed to Enhance Oligodendrogliogenesis and Myelin Repair
Jennifer K. Sabo et al.
PLOS ONE (2013)
Mesenchymal stromal-cell transplants induce oligodendrocyte progenitor migration and remyelination in a chronic demyelination model
J. Jaramillo-Merchan et al.
CELL DEATH & DISEASE (2013)
Transient Proteolytic Modification of Mesenchymal Stromal Cells Increases Lung Clearance Rate and Targeting to Injured Tissue
Erja Kerkela et al.
STEM CELLS TRANSLATIONAL MEDICINE (2013)
The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate
P. Gergely et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Immune mechanisms of new therapeutic strategies in MS - Teriflunomide
Malte C. Claussen et al.
CLINICAL IMMUNOLOGY (2012)
Clinical Pharmacokinetics of Fingolimod
Olivier J. David et al.
CLINICAL PHARMACOKINETICS (2012)
ICV-transplanted human glial precursor cells are short-lived yet exert immunomodulatory effects in mice with EAE
Heechul Kim et al.
GLIA (2012)
CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery
Moa Fransson et al.
JOURNAL OF NEUROINFLAMMATION (2012)
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
Jeffrey A. Cohen et al.
LANCET (2012)
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
Alasdair J. Coles et al.
LANCET (2012)
Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study
Peter Connick et al.
LANCET NEUROLOGY (2012)
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Robert J. Fox et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Ralf Gold et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Human Peripheral Blood Mononuclear Cells Exhibit Heterogeneous CD52 Expression Levels and Show Differential Sensitivity to Alemtuzumab Mediated Cytolysis
Sambasiva P. Rao et al.
PLOS ONE (2012)
Immunomodulation by Transplanted Human Embryonic Stem Cell-Derived Oligodendroglial Progenitors in Experimental Autoimmune Encephalomyelitis
Heechul Kim et al.
STEM CELLS (2012)
Autologous Mesenchymal Stem Cell Therapy in Progressive Multiple Sclerosis: An Open Label Study
Mandana Mohyeddin Bonab et al.
Current Stem Cell Research & Therapy (2012)
Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway
Ralf A. Linker et al.
BRAIN (2011)
Human Glial-Restricted Progenitors Survive, Proliferate, and Preserve Electrophysiological Function in Rats with Focal Inflammatory Spinal Cord Demyelination
Piotr Walczak et al.
GLIA (2011)
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring
Ludwig Kappos et al.
LANCET NEUROLOGY (2011)
Treatment of Brain Inflammatory Diseases by Delivering Exosome Encapsulated Anti-inflammatory Drugs From the Nasal Region to the Brain
Xiaoying Zhuang et al.
MOLECULAR THERAPY (2011)
Long-Term MR Cell Tracking of Neural Stem Cells Grafted in Immunocompetent Versus Immunodeficient Mice Reveals Distinct Differences in Contrast Between Live and Dead Cells
Stacey Cromer Berman et al.
MAGNETIC RESONANCE IN MEDICINE (2011)
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
Paul O'Connor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Tumefactive multiple sclerosis: an uncommon diagnostic challenge
Martha A. Kaeser et al.
JOURNAL OF CHIROPRACTIC MEDICINE (2011)
Safety and Immunological Effects of Mesenchymal Stem Cell Transplantation in Patients With Multiple Sclerosis and Amyotrophic Lateral Sclerosis
Dimitrios Karussis et al.
ARCHIVES OF NEUROLOGY (2010)
Regulation of Gene Expression in Brain Tissues of Rats Repeatedly Treated by the Highly Abused Opioid Agonist, Oxycodone: Microarray Profiling and Gene Mapping Analysis
Hazem E. Hassan et al.
DRUG METABOLISM AND DISPOSITION (2010)
Glatiramer Acetate A Review of its Use in Relapsing-Remitting Multiple Sclerosis and in Delaying the Onset of Clinically Definite Multiple Sclerosis
Natalie J. Carter et al.
DRUGS (2010)
Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: A pilot study
Bassem Yamout et al.
JOURNAL OF NEUROIMMUNOLOGY (2010)
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
Gavin Giovannoni et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Jeffrey A. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system
Volker Brinkmann
BRITISH JOURNAL OF PHARMACOLOGY (2009)
The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers
M. Khademi et al.
EUROPEAN JOURNAL OF NEUROLOGY (2009)
Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial
G. Comi et al.
LANCET (2009)
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
Daniel D. Mikol et al.
LANCET NEUROLOGY (2008)
Interferon-β is neuroprotective against the toxicity induced by activated microglia
Shijie Jin et al.
BRAIN RESEARCH (2007)
Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: Consequences for mode of action in multiple sclerosis
Carolyn A. Foster et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Intrathecal baclofen and morphine in multiple sclerosis patients with severe pain and spasticity
Saud A. Sadiq et al.
JOURNAL OF NEUROLOGY (2007)
Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology
Volker Brinkmann
PHARMACOLOGY & THERAPEUTICS (2007)
The role of Noninvasive cellular imaging in developing cell-based therapies for neurodegenerative disorders
Piotr Walczak et al.
NEURODEGENERATIVE DISEASES (2007)
Interferon-β fails to protect in a model of transient focal stroke
CM Maier et al.
STROKE (2006)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients
J Río et al.
ANNALS OF NEUROLOGY (2006)
Intrathecal drug therapy using the Codman Model 3000 Constant Flow Implantable Infusion Pumps: experience with 17 cases
KD Ethans et al.
SPINAL CORD (2005)
Mitoxantrone treatment of multiple sclerosis - Safety considerations
BA Cohen et al.
NEUROLOGY (2004)
Long term effect (more than five years) of intrathecal baclofen on impairment, disability, and quality of life in patients with severe spasticity of spinal origin
A Zahavi et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2004)
Remyelination, axonal sparing, and locomotor recovery following transplantation of glial-committed progenitor cells into the MHV model of multiple sclerosis
MO Totoiu et al.
EXPERIMENTAL NEUROLOGY (2004)
Mitoxantrone in progressive multiple sclerosis:: a placebo-controlled, double-blind, randomised, multicentre trial
HP Hartung et al.
LANCET (2002)
Glatiramer acetate-specific T-helper 1-and 2-type cell lines produce BDNF:: implications for multiple sclerosis therapy
T Ziemssen et al.
BRAIN (2002)
Local delivery of mitoxantrone for the treatment of malignant brain tumors in rats
F DiMeco et al.
JOURNAL OF NEUROSURGERY (2002)
Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists
S Mandala et al.
SCIENCE (2002)
Linear pontine trigeminal root lesions in multiple sclerosis - Clinical and magnetic resonance imaging studies in 5 cases
I Nakashima et al.
ARCHIVES OF NEUROLOGY (2001)
Cladribine and progressive MS - Clinical and MRI outcomes of a multicenter controlled trial
GPA Rice et al.
NEUROLOGY (2000)
Share Paper
